Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive EGFR-Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study - PubMed
11 hours ago
- #brain-metastases
- #NSCLC
- #EGFR-TKIs
- Study evaluates aumolertinib/icotinib combo for EGFR-mutant NSCLC with brain metastases.
- Phase I/II trial design with dose-escalation and expansion, 24 patients evaluated.
- Recommended Phase II dose: 125 mg icotinib TID + 110 mg aumolertinib QD.
- Median PFS: 21.1 months; median OS: 40.8 months.
- ORR: 95.8%; DCR: 100%; intracranial ORR: 91.7%.
- Grade ≥3 TRAEs in 37.5% patients; common TRAEs: ALT/AST/CK increase, rash.
- Combo shows promising efficacy and tolerable safety, warrants further study.